Milnacipran

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Case reports
Half-life: 6–8 h; Approximate, in adults. Detail in 01.

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: milnacipran · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Serotonergic blunting likely; noradrenergic BP and heart-rate rise stacks.

Human data with psilocybin: Case reports or surveys only
Common practice: Most clinical trials required discontinuation beforehand (Tap 2025); one trial gave psilocybin alongside a continued SSRI (Goodwin 2023). Whether to change the medication is the prescriber's decision.
Half-life: 6–8 h (FDA label, checked 2026-09-30)

Evidence types on this record

CRCase reports or online surveys

3 listed · counted on reports

Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Any change to the dose is the prescriber’s decision. Sources [1]
Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]
Serotonergic: Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [1]

Official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

None linked

No condition named in state rules is linked to this medication.